This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop

This biopharma firm develops therapies for B-cell malignancies and autoimmune diseases, with a focus on oncology and ...

Roche Multiple Sclerosis Drug Meets Main Goal in Late-Stage Trial

With fenebrutinib, the company aims to launch a new oral treatment for multiple sclerosis that offers both greater convenience to patients relative to Ocrevus.
Ibj.com

Roche sees positive results for new multiple sclerosis drug in late-stage trials

Swiss pharmaceuticals powerhouse Roche announced on Saturday that the company’s experimental multiple sclerosis drug met its primary goal in a late-stage trial in patients with a rare form of the ...
GEN

New Potential MS Biomarker Could Inform Drug Response, Disease Progression

A University of Toronto-led study has identified a possible biomarker linked to multiple sclerosis (MS) disease progression. The findings, validated in both mouse and in humans, could help to identify ...
Seeking Alpha

TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis ...

NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TGTX), today announced the presentation of data highlighting BRIUMVI ® (ublituximab-xiiy), to be presented at the Americas Committee ...
Yahoo

Roche's multiple sclerosis drug fenebrutinib meets goal in late-stage trial

Add Yahoo as a preferred source to see more of our stories on Google. The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann/File ...